బయోకెమిస్ట్రీ & అనలిటికల్ బయోకెమిస్ట్రీ

నైరూప్య

Novel Drug Development of the Next-Generation T790M Mutant Specific Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Advanced Non-Small Cell Lung Cancer

Toshio Shimizu and Kazuhiko Nakagawa

Lung cancer is a leading cause of cancer death worldwide. Lung cancer accounts for over 1 million mortalities annually and non-small cell lung cancer (NSCLC) accounts for almost 85% of all cases. Epidermal growth factor receptor (EGFR) mutations are found in approximately 10% and 30% of patients with NSCLC in North American/European and East Asian countries, respectively.